Dasatinib: SFK inhibitorTrastuzumab: Human epidermal growth factor receptor 2 (Her2) inhibitorPaclitaxel: Microtubule inhibitorCondition: Her2-positive metastatic breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.